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Between July 1979 and December 1984, 785 patients re- 
ceived 815 St. Jude Medical valve prostheses. Valve-related 
mortality in the follow-up period was due to thromboem- 
holism in seven cases, anticoagulant-related hemorrhage in 
three and perivalvular leak in two. Freedom from valve- 
related death or reoperation at 3 years was 96.4% for aortic 
valve replacement and 98.3% for mitral valve replacement. 
The overall rate of thromboembolism was 2,6%/patient- 
year with warfarin, 9.2%/patient-year with antiplatelet 
medication and 15,6%/patient-year in patients with no 
anticoagulant therapy. One episode of thrombotic obstruc- 
tion of a mitral valve, in a patient receiving no anticoagu- 
lant therapy, resulted in an occurrence rate of such ob- 
struction of 0.22%/patient-year. 
Valve replacement with the St. Jude valve produced 
excellent clinical results, but long-term anticoagulation 
with warfarin was required to minimize thromboembolic 
complications. The use of antiplatelet agents alone provided 
inadequate protection. 
(J Am Co11 Cardiol1989;13:57-62) 
The St. Jude Medical valve is a bileaflet. low profile mechan- 
ical prosthesis made of Pyrolite carbon (CarboMedics, Inc.). 
Early studies demonstrated its superior flow characteristics 
(I ,2) and low short-term complication rate (3-5). Because of 
these design characteristics. it was anticipated that antico- 
agulation with warfarin would be less critical for avoidance 
of thromboembolic complications. The purpose of this re- 
port is to examine the outcome of operation in a large series 
of patients and determine the relation between postoperative 
thromboembolism and the methods of anticoagulation em- 
ployed. 
Methods 
Study patients. All patients who underwent aortic, mitral 
or combined aortic and mitral valve replacement with the St. 
Jude Medical valve between July 1979 and December 1984 
were included in this study. Patients undergoing double 
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valve replacement in which the second valve was other than 
a St. Jude valve and patients undergoing tricuspid valve 
replacement were excluded. There were 309 female and 476 
male subjects. with a mean age of 57. I years (range I4 to 85). 
A total of 815 valves were implanted in 785 patients. Aortic 
valve replacement was carried out in 491 patients, mitral 
valve replacement in 264 patients and double valve replace- 
ment in 30 patients. Reoperation was performed to replace a 
previously implanted non-St. Jude prosthetic valve in the 
aortic position in I9 (3.9%) of 491 patients and in the mitral 
position in I4 (5.3%) of 264 patients. Associated procedures 
were performed in 354 (45.0%) of the 7X5 patients (Table 1). 
the most common being coronary artery bypass grafting in 
213 patients (27. I%), followed by ascending/arch aortic 
aneurysm repair with or without coronary or arch vessel 
reimplantation in 76 patients (9.6%). 
Surgical technique. The surgical technique employed 
consisted of the use of moderate systemic hypothermia on 
total cardiopulmonary bypass and cardioplegic arrest of the 
heart. After complete valvular leaflet excision, interrupted 
everting horizontal mattress or figure-of-eight sutures of 2-O 
polyester were used to seat the valve. The prosthetic valve 
commissural orientation in the anulus was variable and could 
not be analyzed in this study. 
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Table 1. Associated Procedures Performed at the Time of St. Jude Prosthetic Valve Replacement 
in 785 Patients 
Associated Procedures AVR MVR DVR 
Coronary artery bypass 
Ascending aorti: aneurysm repair 
Ascending aork aneurysm repair t 
reimplantation of coronary or 
arch vessels, or both 
Mitral valvuloplasty 
Tricuspid annuloplasty 
Other 
146 61 6 
27 0 0 
48 0 I 
20 0 0 
1 7 2 
23 11 I 
AVR = aortic valve replacement; DVR = double valve replacement; MVR = mitral valve replacement. 
Definitions. Operative mortality was defined as death 
within 30 days of surgery. Late mortality comprised all 
deaths occurring beyond the initial 30 day postoperative 
period. 
A thromboembolic episode was dejined as any acute focal 
neurologic deficit, either transient or permanent, or periph- 
eral embolus diagnosed clinically or at embolectomy. Neu- 
rologic events occurring in the immediate perioperative 
period were not considered to be valve-related events. 
The severity of hemorrhage was defined as mild if no 
hospital admission was required for treatment, moderate if 
hospitalization but no blood transfusion was required and 
severe if hospitalization with blood transfusion was re- 
quired. 
Valve-related death was dejined as death due to throm- 
boembolism, anticoagulant-related hemorrhage, valve 
thrombosis, endocarditis, perivalvular leak or mechanical 
failure. Fatal strokes were considered to be valve-related 
unless another cause was apparent. 
Follow-up. All patients were contacted by telephone. 
When necessary, further information was obtained from the 
primary care physician. Foreign patients (n = 89) were 
Figure 1. Kaplan-Meier curves of probability of freedom from any Figure 2. Kaplan-Meier curves of probability of freedom from any 
thromboembolic event according to the anticoagulant regimen em- hemorrhagic complications according to the anticoagulant regimen 
ployed. Note that as a result of censoring of the patient at the initial employed. As in Figure 1, censoring of the patient at the initial event 
event, subsequent events are not accounted for in this analysis. resulted in the exclusion of subsequent events in this analysis. 
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included in the operative analysis but not in the follow-up 
data. Follow-up was complete in 95.4% of nonforeign pa- 
tients, and each patient had an average of 3.1 contacts in the 
follow-up period. The cumulative duration of follow-up for 
the entire group was 19,117 patient-months (mean 30.6 
months). 
Statistical analysis. The data were entered into a custom- 
designed data base management system implemented in 
ANS-MUMPS (ANSI x 11.1-1983). The time-related free- 
dom from thromboembolism or hemorrhage was analyzed by 
Kaplan-Meier analysis. The standard error computation for 
Kaplan-Meier analysis was done according to the method of 
Peto et al. (6). In the Kaplan-Meier analyses of freedom from 
hemorrhagic and thromboembolic complications, the occur- 
rence of an event resulted in censoring of the patient at that 
point. Thus, multiple events in a single patient appear only 
as the initial event in that patient. Patients were analyzed 
according to the anticoagulant regimen present at the time of 
hospital discharge (Fig. 1 and 2), and a subsequent change in 
anticoagulant therapy led to censoring of the patient at the 
time of that change. The data shown in Tables 2 and 3 
include all the time and events accumulated on individual 
WU 
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Table 2. Incidence of Thromboembolic Events and the Number of Patients Experiencing Them 
According to the Anticoagulant Regimen Present at the Time of the Event 
Warfarin .4ntiplatelet None Total 
A 
Months on each therapy 
No. observed events 
No. expected events 
I( 
Months on each therapy 
No. observed patients 
No. expected patients 
(‘ 
Months on each therapy 
No. observed events 
Kate (per pt-yr) 
14.x.59 1.471 384 
32 19 5 
47.0 7.81 1.21 
2 = 9.83; p = 0.007 for differences among groups 
14.859 2.471 384 
31 I5 5 
42.x 7.09 I.12 
,$ = 7.18: p = 0.0276 for differences among groups 
14.859 2.471 384 
32 19 5 
2.58% 9.23% 15.6% 
,$ = 9.83; p = 0.007 for differences among groups 
17.71-t 
56 
56.02 
17.714 
51 
51.01 
17.714 
56 
3.79LF 
A = Total number of events according to anticoagulant regimen. with a comparison of expected and actual event 
tatea: B = number of patients with events according to anticoagulant regimen. with a comparison of expected and 
actual event rates: C = comparison of linearized rates of events according to anticoagulant regimen: pt-yr = patient- 
vear. 
regimens and, thus, account for all events on those regimens 
and all changes of therapy. In Tables 2 and 3. the expected 
values were computed using the null hypothesis that as- 
sumes that the anticoagulant regimen did not influence the 
rate of complications (that is, that the rate is the same for all 
regimens’). Therefore, the expected events were computed 
by multiplying the total number of hemorrhagic and throm- 
boembolic events by the proportion of follow-up time on 
each anticoagulant regimen. 
Results 
Operative mortality. Operative mortality rate for the en- 
tire group of patients was 6.7% (53 of 785 patients). Opera- 
tive mortality rate for aortic valve replacement was 5.1% (25 
of 491 patients)-2.1% (5 of 237 patients) for isolated aortic 
valve replacement and 7.9% (20 of 254 patients) for aortic 
valve replacement and associated procedures. Operative 
mortality rate for mitral valve replacement was 9.5% (25 of 
264 patients)-5.6% (IO of 179 patients) for isolated mitral 
valve replacement and 17.6% (15 of 85 patients) for mitral 
valve replacement with associated procedures. Operative 
mortality rate for double valve replacement was 10% (3 of 30 
patients)-4% (I of 2.5 patients) for double valve replacement 
alone and 40% (2 of 5 patients) for double valve replacement 
with associated procedures. The most common causes of 
early death were low output syndrome (18 patients), arrhyth- 
mias (8 patients) and perioperative myocardial infarction (6 
patients). The intraaortic balloon pump was used in 2.8, 4.9 
and 3.3%, respectively, of cases of aortic, mitral and double 
valve replacement. 
Overall survival. The overall patient survival rate (LSE) 
as determined by Kaplan-Meier analysis was 88.5 t 1.98% 
at 3 years of follow-up. Survival at 3 years was 90.9 ? 2.2% 
for aortic valve replacement, 83.2 ? 4.2% for mitral valve 
replacement and 93.8 t 8.3% for double valve replacement. 
The causes of late death are listed in Table 4; the cause of 
death was unknown in five patients. 
Complications. Reoperation for valve-related problems 
was required in 10 patients-for perivalvular leak in 6, 
endocarditis in 3 and partial thrombotic obstruction in 1 
patient. A history of endocarditis before performance of 
valve replacement was present in one each of the patients 
who required reoperation for perivalvular leak and endocar- 
ditis. One patient died after reoperation for perivalvular 
leak; the other nine patients survived. 
Freedom from valve-related death or reoperation at 3 
years was 96.4 + 1.5% for aortic valve replacement and 98.3 
-C 1.6% for mitral valve replacement. The Kaplan-Meier 
curve of probability of freedom from valve-related death or 
reoperation for each category of valve replacement is shown 
in Figure 3. 
Anticoagulation and thromhoemholism. At the time of 
first follow-up, 625 patients were alive and living in North 
America. It was possible to obtain information regarding 
anticoagulant status in 610 of these patients. Warfarin anti- 
coagulation was administered in 518 patients, aspirin and 
dipyridamole in 24, aspirin alone in 5 and dipyridamole alone 
in 22. The remaining 41 patients were taking neither warfarin 
nor antiplatelet agents. 
The total incidence of thvomboembolic events is shown in 
Trrble 2. Events are reported according to the anticoagulant 
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Table 3. Incidence and Severity of Hemorrhagic Events According to the Anticoagulant Regimen Present at the Time of the Event 
A No. Patients 
No. Mild No. Moderate No. Severe No. Fatal 
Events Events Events Events 
Warfarin 129 85 36 32 3 
Antiplatelet 8 2 2 4 0 
Nothing 2 0 I I 0 
Total l36* 87 39 37 3 
B 
Months on each 
therapy 
No. observed 
events 
No. expected 
events 
Warfarin 
14,859 
71 
66.3 
Antiplatelet 
2,471 
6 
II.0 
2 = 2.673; p = 0.2621 for differences among groups 
None 
384 
2 
1.71 
Total 
17,714 
79 
C 
Total Time on 
Therapy (months) No. Events 
Rate 
(per pt-yr) 
Coumadin 14,859 
Antiplatelet 2,471 
None 384 
Total 17,714 
71 5.73% 
6 2.91% 
2 6.25% 
79 5.35% 
2 = 1.65: p = 0.4383 for differences among groups 
*Three patients had events on more than one medication. A = Total number and severity of events according to anticoagulant status; B = number of 
moderate, severe and fatal events according to anticoagulant regimen, with a comparison of expected and actual event rates; C = comparison of linearized rates 
of moderate, severe and fatal events according to anticoagulant regimen; pt-yr = patient-year. 
status of the patients at the time of the event, and all time 
accumulated on each regimen is tabulated. The overall rate 
of thromboembolic events was 2.6%/patient-year in patients 
receiving warfarin, 9.2%/patient-year in patients receiving 
antiplatelet medication (aspirin or dipyridamole, or both) 
only and 15.6%/patient-year in those patients receiving no 
anticoagulant therapy. The differences among these rates 
were highly significant. The rate for specific valve sites for 
patients maintained on warfarin postoperatively was 2.0%/ 
patient-year for aortic valve replacement, 3.9%/patient-year 
for mitral valve replacement and O%/patient-year for double 
Table 4. Causes of Late Death in 785 Patients 
Cause of Death AVR MVR DVR 
Valve-related 
Thromboembolism 
Hemorrhage 
Perivalvular leak 
Nonvalve-related 
Cardiac failure 
Pulmonary insufficiency 
Malignancy 
Myocardial infarction 
Renal 
Other 
Unknown 
6 1 
2 1 
2 
7 IO 
3 5 
5 2 
3 2 I 
I 2 
5 3 
2 3 
valve replacement. The Kaplan-Meier analysis of the rela- 
tion of valve site to the incidence of thromboembolism is 
shown in Figure 4. Freedom from thromboembolic compli- 
cations at 3 years was 92.4 + 2.1% for aortic valve replace- 
ment and 85.1 2 4.4% for mitral valve replacement. 
The incidence and severity of anticoagulant-related hem- 
orrhage according to the anticoagulant regimen is shown in 
Table 3. The total rates of moderate, severe or fatal hemor- 
rhagic events were not significantly different. However, 
Figure 3. Kaplan-Meier curves of probability of freedom from 
valve-related mortality or reoperation (see text for definition of 
valve-related mortality). 
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Figure 4. Kaplan-Meier curve5 of probability of freedom from 
thromboembolism according to the xite of implantation of the St. 
Jude prosthesis. 
Kaplan-Meier analysis curves of the probability of complete 
freedom from any episode of mild. moderate. severe or fatal 
hemorrhage demonstrated highly significant differences 
among the groups (Fig. 2). 
Tlzr~ WNS OMJ episode 04’ rlumlhotic oh.\ trrrcrim of ~1 
mitrrd IY~LY. resulting in a linearized occurrence rate of 
0.22%/patient-year. This occurred in a patient who received 
no postoperative anticoagulant therapy because of chronic 
immune thrombocytopenia. She underwent successful reop- 
eration. and a Carpentier-Edwards valve was implanted. 
There were no cases of aortic valve thrombotic obstruction. 
Of the 610 prrtients \iitlz umplcte infomrrtior~ uholrt 
mticocrgulunf status, 476 remained on the same regimen 
prescribed at hospital discharge and 134 had a change of 
regimen during the follow-up period. There were no differ- 
ences among the clinical characteristics of these patients in 
regard to age, gender, site of valve implantation, presence or 
absence of a previously implanted valve prosthesis or overall 
late mortality (p :, 0.05 for all analyses). 
7’1~ tlc.0 most common rrrrsons jkw rcgimrli c~liurige b~wc 
hc~morrhugic or rhrornhormholic everrts. Of the 476 patients 
who were maintained on a constant regiment. 37 (7.8%) had 
had a hemorrhage compared with 27 (20. I%) of the 134 
patients who had a regimen change (p < 0.0001). Similarly 
only 29 (6.1%) of the 476 patients who were on a constant 
regimen had had a thromboembolic event compared with 25 
(18.7%) of the 134 patients who had had a regimen change. 
Thus, we were unable to identify patients who were at 
unusually high risk for hemorrhage or thromboembolism. 
Preoperatively. 74.8% of patients were in New York 
Heart Association functional class III or 1V. including I5 
patients (1.9%) whose hemodynamic instability warranted 
emergency surgery. Postoperatively 93% of patients were in 
functional class I or II. 
Discussion 
The St. Jude valve was designed to achieve optimal 
durability and low thrombogenicity. Several studies (1,7,8) 
have confirmed its excellent flow characteristics. Although 
leaflet dislodgment (9) or embolization (10) has occurred. 
mechanical failure has been rare. Several large series (ll- 
13). including the present studies. have reported follow-up 
data on large numbers of patients with no episodes of 
mechanical failure or dysfunction. 
Incidrrlcr c?f’ thro&oernholic c~ornpliccctions. It was 
hoped that the design features of the St. Jude valve would 
reduce or eliminate the need for long-term anticoagulant 
therapy found necessary for other mechanical prostheses. 
Early studies (14.15) suggested a relatively decreased inci- 
dence of thromboembolic complications. However, several 
reports as well as the present report indicate that the 
incidence of thromboembolic complications has been com- 
parable with that seen with the other types of mechanical 
prostheses. The linearized rate of thromboembolism of 
2.O%/patient-year in our patients receiving warfarin after 
aortic valve replacement was similar to results reported in 
comparable series (2.1%/patient-year by Czer et al. 11 Il. 
2.6%/patient-year by Burckhardt et al. [9] and 2S%/patient- 
year by Kinsley et al. 1161). The linearized rate of throm- 
boembolism in patients receiving warfarin after mitral valve 
replacement in our series was 3.9%/patient-year. This is 
slightly higher. although comparable. with previously pub- 
lished results (1.7%/patient-year by Czer et al. [Ill, 2.9%/ 
patient-year by Burckhardt et al. [9] and 2,7%/patient-yeal 
by Kinsley et al. [ 161). 
Role of anticoagulant therapy with warfarin. In our expe- 
rience, the rate of thromboembolism in the absence of 
anticoagulation with warfarin was unacceptably high (9.2%/ 
patient-year on antiplatelet therapy only and 1.5.6%/patient- 
year on no anticoagulant therapy compared with 2.6%/ 
patient-year in patients on warfarin). These results are very 
similar to those reported by Beaudet et al. ( 12). who noted a 
thromboembolic rate of 6. I %/patient-year after aortic valve 
replacement and 16.6%/patient-year after mitral valve re- 
placement in the absence of anticoagulation. Similarly, Czer 
et al. (I I) reported a thromboembolic rate of 7,7%/patient- 
year in patients who did not receive anticoagulant therapy 
with warfarin. 
These data also resemble those previously reported by us 
for the Smeloti-Cutter (17) and the DeBakey-Surgitool (18) 
aortic prostheses. In both studies, we found the lowest rates 
of thromboembolism on warfarin and unacceptable rates 
when patients received no anticoagulant. The Smeloff-Cutter 
prosthesis derived some protection from aspirin and dipyri- 
damole, as did the St. Jude prosthesis in this study. How- 
ever, patients with the DeBakey-Surgitool aortic valve, a 
Pyrolite composite valve of the ball in cage design, derived 
no benefit from aspirin or dipyridamole. 
62 MYERS ET AL. 
ST. JUDE VALVE PROSTHESIS AND SYSTEMIC ANTICOAGULATION 
JACC Vol. 13, No. 1 
January 1989:57-62 
Role of aspirin-dipyridamole therapy. Ribeiro et al. (19) 
followed-up a group of 67 patients who received antiplatelet 
medication (aspirin and dipyridamole) only after placement 
of an aortic St. Jude valve. The incidence of aortic valve 
thrombosis was 2.l%/patient-year in patients undergoing 
aortic valve replacement alone and lO%/patient-year in 15 
patients who had undergone aortic valve replacement plus 
mitral valve replacement (Carpentier-Edwards bioprosthesis 
in 8; St. Jude valve in 7). Beaudet et al. (12) reported an 
incidence rate of aortic valve thrombosis of 6,l%/patient- 
year and mitral valve thrombosis of 5S%/patient-year in 
patients receiving no anticoagulant therapy, as opposed to 
no such episodes in the group receiving anticoagulant ther- 
apy. The incidence of aortic valve thrombosis was 0.1 l%/ 
patient-year and mitral valve thrombosis O.SO%/patient-year 
in the series of Kinsley et al. (16), and a history of erratic or 
deficient anticoagulant therapy was noted in all patients who 
suffered this complication. 
Bleeding complications. Anticoagulant therapy is associ- 
ated with the risk of bleeding complications. The incidence 
of moderate and severe nonfatal anticoagulant-related hem- 
orrhage was 5.4%/patient-year in the present St. Jude valve 
series. Although the total rates of moderate, severe and fatal 
hemorrhages were not significantly different among the three 
groups, three deaths were clearly attributable to warfarin 
therapy. There were two cases of cerebral hemorrhage and 
one of pericardial tamponade. Furthermore, there were 
highly significant differences among the number of patients 
free of mild, moderate or severe or fatal hemorrhagic com- 
plications (Fig. 2). Although there is a tendency to underes- 
timate the significance of anticoagulant-related morbidity, 
Kinsley et al. (16) noted that anticoagulant-related hemor- 
rhage was the single most important cause of valve-related 
mortality in their series. 
Clinical implications. Our experience with the St. Jude 
valve prosthesis supports the favorable clinical impression 
reported by others. Nevertheless, the St. Jude valve pros- 
thesis retains a risk of thromboembolic complications com- 
parable with that with other mechanical valve prostheses, 
thus necessitating the use of long-term warfarin anticoagu- 
lation, despite the significant risk of anticoagulant-induced 
hemorrhage. 
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